Free tool
FAERS Monitor: Cardiogen-82
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019414 or its brand name (Cardiogen-82, Rubidium Chloride Rb-82). Reports on generic versions are filed under their own applications.
Reports
116
Serious
38
33% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event76
- expired product administered26
- wrong technique in product usage process23
- product preparation error21
- radiation overdose8
- off label use6
- drug ineffective5
- exposure to radiation5
- therapeutic response unexpected4
- wrong technique in drug usage process4
- drug effect decreased3
- intercepted product administration error3
- product quality issue3
- alopecia2
- device malfunction2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 7 |
| 2015 | 21 |
| 2016 | 6 |
| 2018 | 13 |
| 2019 | 18 |
| 2020 | 12 |
| 2022 | 18 |
| 2023 | 11 |
| 2024 | 3 |
| 2025 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,043 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radiation overdoseSignal | 8 | 31565.3 | 15235.6 | 189,050 |
| exposure to radiationSignal | 5 | 7500.0 | 3124.1 | 29,161 |
| product preparation errorSignal | 21 | 185.5 | 125.9 | 3,672 |
| expired product administeredSignal | 26 | 141.9 | 101.2 | 3,502 |
| no adverse eventSignal | 76 | 76.1 | 66.7 | 5,603 |
| intercepted product administration errorSignal | 3 | 71.0 | 23.2 | 143 |
| wrong technique in product usage processSignal | 23 | 20.6 | 14.3 | 413 |
| wrong technique in drug usage processSignal | 4 | 20.0 | 7.6 | 54 |
| therapeutic response unexpectedSignal | 4 | 16.2 | 6.2 | 43 |
| drug effect decreasedSignal | 3 | 10.1 | 3.3 | 16 |
| device malfunction | 2 | 5.2 | 1.3 | 3 |
| product quality issueSignal | 3 | 4.0 | 1.3 | 4 |
| alopecia | 2 | 1.8 | 0.5 | 0 |
| off label use | 6 | 1.2 | 0.6 | 0 |
| drug ineffective | 5 | 0.7 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.